Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 213 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geriatric Cancer Patients Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
tipifarnib, etoposide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
70 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced May 22, 2026, 1:36 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
Interventions
Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 22, 2026, 1:36 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Geriatric Cancer Patients
Interventions
G8 Screening Tool
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced May 22, 2026, 1:36 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Adjuvant hypofractionation, Definitive Hypofractionation
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
70 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced May 22, 2026, 1:36 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
92
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced May 22, 2026, 1:36 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Myelogenous Leukemia, Acute, Myelodysplastic Syndromes
Interventions
MGCD0103
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Kansas City, Missouri • Rochester, New York • Canton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced May 22, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Nab-Paclitaxel
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
70 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
Fayetteville, Arkansas • Chapel Hill, North Carolina • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced May 22, 2026, 1:36 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
geriatric co-management, geriatric guided supportive care
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced May 22, 2026, 1:36 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
211
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 171 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 1:36 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bendamustine, melphalan, Autologous Stem Cell Transplantation (ASCT)
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced May 22, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Bendamustine, Ofatumumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
70 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Fort Myers, Florida • Pensacola, Florida • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced May 22, 2026, 1:36 AM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Cancer, Rectal
Interventions
Short course radiation therapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
70 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced May 22, 2026, 1:36 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS, High-grade B-cell Lymphoma, Multiple Myeloma
Interventions
Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go, Cognition, Geriatric Depression Scale, Social Support, Brief Test of Attention, Trail Making Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, Blood draw
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 22, 2026, 1:36 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Multiple Myeloma, Cancer
Interventions
Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced May 22, 2026, 1:36 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Velcade, Idarubicin
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Lexington, Kentucky • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2010 · Synced May 22, 2026, 1:36 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Urinary Tract
Interventions
Deep Neuromuscular Blockade (NMB), Moderate Neuromuscular Blockade (NMB), Sugammadex, Neostigmine, Pain Assessment
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced May 22, 2026, 1:36 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration, Interview, Educational Intervention, Assessment, Internet-Based Intervention, Electronic Health Record Review
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
24
States / cities
Tuscaloosa, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 22, 2026, 1:36 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Placebo, Volasertib, Cytarabine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
65 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Duluth, Minnesota • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced May 22, 2026, 1:36 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Acalabrutinib, Rituximab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
65 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
14
States / cities
Berkeley, California • La Jolla, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
bevacizumab, Erlotinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
70 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Galloway, New Jersey • Mount Holly, New Jersey • Paoli, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced May 22, 2026, 1:36 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma
Interventions
Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide
Procedure · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced May 22, 2026, 1:36 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Sarcoma
Interventions
Doxorubicin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced May 22, 2026, 1:36 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Elderly
Interventions
Azacitidine
Drug
Lead sponsor
Kansas City Veteran Affairs Medical Center
Federal
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced May 22, 2026, 1:36 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, etoposide, lomustine, procarbazine hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2011 · Synced May 22, 2026, 1:36 AM EDT